CD274 and neoplasm: Although current therapies that disrupt tumor immune evasion through ICB, including antibody-mediated blockade of PD-L1 binding to its cognate receptor, PD-1, have shown potent antitumor efficacy in 15–20% of patients, whereas immune evasion and therapeutic resistance lead to weaker clinical responses through largely unknown mechanisms in the majority of patients7–9.